These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33990514)

  • 1. Current Pharmacological Management of Aortic Aneurysm.
    Xiang B; Zhu S; Li J; Lai H; Wang C; Zhu K
    J Cardiovasc Pharmacol; 2021 Aug; 78(2):211-220. PubMed ID: 33990514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localized Antileptin Therapy Prevents Aortic Root Dilatation and Preserves Left Ventricular Systolic Function in a Murine Model of Marfan Syndrome.
    Fisch S; Bachner-Hinenzon N; Ertracht O; Guo L; Arad Y; Ben-Zvi D; Liao R; Schneiderman J
    J Am Heart Assoc; 2020 May; 9(10):e014761. PubMed ID: 32378446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-coding RNAs in aneurysmal aortopathy.
    Spin JM; Li DY; Maegdefessel L; Tsao PS
    Vascul Pharmacol; 2019 Mar; 114():110-121. PubMed ID: 29909014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The oral administration of clarithromycin prevents the progression and rupture of aortic aneurysm.
    Uchida W; Narita Y; Yamawaki-Ogata A; Tokuda Y; Mutsuga M; Lee Fujimoto K; Abe T; Oshima H; Usui A
    J Vasc Surg; 2018 Dec; 68(6S):82S-92S.e2. PubMed ID: 29550174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of a Nonpeptide Angiotensin II Type 2 Receptor Agonist, Compound 21, on Aortic Aneurysm Growth in a Mouse Model of Marfan Syndrome.
    Verbrugghe P; Verhoeven J; Clijsters M; Vervoort D; Schepens J; Meuris B; Herijgers P
    J Cardiovasc Pharmacol; 2018 Apr; 71(4):215-222. PubMed ID: 29300219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AT1 receptor antagonism to reduce aortic expansion in Marfan syndrome: lost in translation or in need of different interpretation?
    Mallat Z; Daugherty A
    Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):e10-2. PubMed ID: 25550201
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update.
    Wang YD; Liu ZJ; Ren J; Xiang MX
    Curr Vasc Pharmacol; 2018 Jan; 16(2):114-124. PubMed ID: 28412911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.
    Gambarin FI; Favalli V; Serio A; Regazzi M; Pasotti M; Klersy C; Dore R; Mannarino S; Viganò M; Odero A; Amato S; Tavazzi L; Arbustini E
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):354-62. PubMed ID: 19430350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvianolic acid A, a matrix metalloproteinase-9 inhibitor of Salvia miltiorrhiza, attenuates aortic aneurysm formation in apolipoprotein E-deficient mice.
    Zhang T; Xu J; Li D; Chen J; Shen X; Xu F; Teng F; Deng Y; Ma H; Zhang L; Zhang G; Zhang Z; Wu W; Liu X; Yang M; Jiang B; Guo D
    Phytomedicine; 2014 Sep; 21(10):1137-45. PubMed ID: 24916705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism.
    Habashi JP; Doyle JJ; Holm TM; Aziz H; Schoenhoff F; Bedja D; Chen Y; Modiri AN; Judge DP; Dietz HC
    Science; 2011 Apr; 332(6027):361-5. PubMed ID: 21493863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
    Sorice GP; Folli F
    Med Hypotheses; 2009 Oct; 73(4):614-8. PubMed ID: 19577852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic mechanisms and the potential of drug therapies for aortic aneurysm.
    Liu B; Granville DJ; Golledge J; Kassiri Z
    Am J Physiol Heart Circ Physiol; 2020 Mar; 318(3):H652-H670. PubMed ID: 32083977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol Inhibits Aortic Root Dilatation in the Fbn1C1039G/+ Marfan Mouse Model.
    Hibender S; Franken R; van Roomen C; Ter Braake A; van der Made I; Schermer EE; Gunst Q; van den Hoff MJ; Lutgens E; Pinto YM; Groenink M; Zwinderman AH; Mulder BJ; de Vries CJ; de Waard V
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1618-26. PubMed ID: 27283746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening aortic drug treatments through arterial compliance measurements.
    Rentschler ME; Baxter BT
    Curr Vasc Pharmacol; 2008 Oct; 6(4):250-7. PubMed ID: 18855713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of the pharmacological management of aortic root dilation in Marfan syndrome.
    Thakur V; Rankin KN; Hartling L; Mackie AS
    Cardiol Young; 2013 Aug; 23(4):568-81. PubMed ID: 23083542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KLF15 Overexpression Protects β-Aminopropionitrile-Induced Aortic Rupture in Rodent Model via Inhibiting Connective Tissue Growth Factor.
    Zhan B; Hu Z; Chen J; Zhu R; Zhao H; Yang J; Zhang Z; Nie R
    Thorac Cardiovasc Surg; 2017 Mar; 65(2):120-125. PubMed ID: 26600407
    [No Abstract]   [Full Text] [Related]  

  • 17. Amelioration of salvianolic acid C on aortic structure in apolipoprotein E-deficient mice treated with angiotension II.
    Wu P; Han N; Yu H; Wang L; Li X; Dong Z; Fu W; Yorinaka H; Cho K; Wu W; Liu X; Yang M; Guo DA; Yin J; Jiang B
    Life Sci; 2016 Dec; 166():75-81. PubMed ID: 27663582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome.
    Arce C; Rodríguez-Rovira I; De Rycke K; Durán K; Campuzano V; Fabregat I; Jiménez-Altayó F; Berraondo P; Egea G
    Arterioscler Thromb Vasc Biol; 2021 Sep; 41(9):e440-e452. PubMed ID: 34162229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomics reveals Rictor as a noncanonical TGF-β signaling target during aneurysm progression in Marfan mice.
    Parker SJ; Stotland A; MacFarlane E; Wilson N; Orosco A; Venkatraman V; Madrid K; Gottlieb R; Dietz HC; Van Eyk JE
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1112-H1126. PubMed ID: 30004239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation.
    Ding Y; Li X; Zhou M; Cai L; Tang H; Xie T; Shi Z; Fu W
    Vascul Pharmacol; 2021 Feb; 136():106818. PubMed ID: 33227452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.